A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

Red, itchy, and scaly skin from atopic dermatitis and eczema can be uncomfortable, confusing, and all too familiar.

Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Evommune launches mid-stage trials for immune-modulating drugs targeting skin conditions, backed by $115M funding and led by ...

Atopic dermatitis (AD) is a widespread, chronic inflammatory skin condition that can affect patients of all ages and is the result of a complex interplay of environmental, immunological ...

The atopic dermatitis app will launch first in the UK, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan later in 2022. Image Phil Taylor ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

Skin and subcutaneous diseases account for 44.84 million DALYs globally in 2021, ranking seventh in disability burden.

Children with inflammatory skin diseases are at an increased risk for sleep and psychological disorders, prompting clinicians ...

The discovery of the association of FLG mutations with atopic diseases followed insights into a common disorder of keratinization, ichthyosis vulgaris. The epidermis of individuals with AD shows a ...